Dyne Therapeutics, Inc. (DYN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 78.03M USD | Liabilities, Current |
| Cash and equivalents | 676.11M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 222.36M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $78.03M | $676.11M | $222.36M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $51.25M | $753.10M | $219.05M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $50.63M | $893.37M | $217.19M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $59.85M | $573.61M | $218.28M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $41.47M | $485.04M | $198.88M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $33.88M | $472.25M | $205.24M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $42.26M | $435.45M | $206.82M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $43.26M | $532.16M | $191.51M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $29.75M | $608.20M | $170.64M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $22.36M | $272.04M | $181.51M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $51.09M | $121.63M | $1.47M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $29.69M | $130.28M | $27.54M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $20.22M | $167.61M | $40.13M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $21.59M | $181.11M | $57.10M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $28.09M | $172.15M | $83.86M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $23.32M | $144.90M | $103.24M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $25.62M | $135.98M | $155.86M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $23.24M | $147.97M | $175.19M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $28.72M | $200.82M | $175.75M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $23.35M | $229.04M | $178.48M | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $258.38M | $177.20M | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $310.95M | $172.14M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $10.97M | $300.85M | $44.46M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $4.68M | $379.61M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.36M | $14.63M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |